BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Dominguez-Molina B, Machmach K, Perales C, Tarancon-Diez L, Gallego I, Sheldon JL, Leal M, Domingo E, Ruiz-Mateos E. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells. J Virol 2018;92:e01219-18. [PMID: 30232187 DOI: 10.1128/JVI.01219-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Liu L, Al-Dhamin Z, Yuan X, Cui L, Yang Y, Zhao W, Zhang Y, Fu N, Nan Y. Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis. Histol Histopathol 2020;35:1309-18. [PMID: 33063838 DOI: 10.14670/HH-18-269] [Reference Citation Analysis]
3 Farshadpour F, Taherkhani R, Bakhtiari F. Prevalence and Predominant Genotype of Hepatitis C Virus Infection and Associated Risk Factors among Pregnant Women in Iran. Biomed Res Int 2021;2021:9294276. [PMID: 34589552 DOI: 10.1155/2021/9294276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 El Aggan H, Farahat N, El Deeb N, Zeid A, El-Shendidi A. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury. Microb Pathog 2019;131:65-74. [PMID: 30926417 DOI: 10.1016/j.micpath.2019.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Brenner N, Mentzer AJ, Butt J, Braband KL, Michel A, Jeffery K, Klenerman P, Gärtner B, Schnitzler P, Hill A, Taylor G, Demontis MA, Guy E, Hadfield SJ, Almond R, Allen N, Pawlita M, Waterboer T. Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS One 2019;14:e0210407. [PMID: 30615688 DOI: 10.1371/journal.pone.0210407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Wei K, Jiang BC, Guan JH, Zhang DN, Zhang MX, Wu JL, Zhu GZ. Decreased CD4+CD25+CD127dim/- Regulatory T Cells and T Helper 17 Cell Responsiveness to Toll-Like Receptor 2 in Chronic Hepatitis C Patients with Daclatasvir Plus Asunaprevir Therapy. Viral Immunol 2018;31:559-67. [PMID: 30067145 DOI: 10.1089/vim.2018.0055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Farshadpour F, Taherkhani R. Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations. Med Princ Pract 2021. [PMID: 33882487 DOI: 10.1159/000516693] [Reference Citation Analysis]
8 Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. Int J Drug Policy 2019;72:91-8. [PMID: 31129023 DOI: 10.1016/j.drugpo.2019.05.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
9 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Reference Citation Analysis]
10 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mammari N, Krier Y, Albert Q, Devocelle M, Varbanov M, On Behalf Of The Oemonom. Plant-Derived Antimicrobial Peptides as Potential Antiviral Agents in Systemic Viral Infections. Pharmaceuticals (Basel) 2021;14:774. [PMID: 34451871 DOI: 10.3390/ph14080774] [Reference Citation Analysis]
12 Sira J, Brown M, Ambegaokar S, Modin L, Kelly DA. The necessity of education and hepatitis B vaccination for young people: A study of high risk behaviour for blood borne viruses in the United Kingdom. J Child Health Care 2019;23:437-45. [PMID: 30818996 DOI: 10.1177/1367493519831499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Kassa Y, Million Y, Biset S, Moges F. Hepatitis B and Hepatitis C Viral Infections and Associated Factors Among Prisoners in Northeast Ethiopia. J Blood Med 2021;12:561-70. [PMID: 34267568 DOI: 10.2147/JBM.S314556] [Reference Citation Analysis]
14 Damola AB, Adeniji JA, Bakarey AS. Hepatitis C virus seropositivity and the risk factors for transmission among blood donors in some selected centers in Lagos State, Southwest Nigeria. J Immunoassay Immunochem 2019;40:528-39. [PMID: 31378189 DOI: 10.1080/15321819.2019.1647853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49:99-106. [PMID: 30467877 DOI: 10.1111/apt.15043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Taherkhani R, Taherkhani S, Farshadpour F. Dynamics of host immune responses to SARS-CoV-2. World J Clin Cases 2021; 9(18): 4480-4490 [PMID: 34222416 DOI: 10.12998/wjcc.v9.i18.4480] [Reference Citation Analysis]
17 Liu Y, Zou X, Chen W, Gong C, Ling L. Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. Int J Environ Res Public Health 2019;16:E4436. [PMID: 31726750 DOI: 10.3390/ijerph16224436] [Reference Citation Analysis]
18 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
19 Wang Y, Zhao Z, Wang M, Hannah MN, Hu Q, Rui J, Liu X, Zhu Y, Xu J, Yang M, Cui JA, Su Y, Zhao B, Chen T. The transmissibility of hepatitis C virus: a modelling study in Xiamen City, China. Epidemiol Infect 2020;148:e291. [PMID: 33234178 DOI: 10.1017/S0950268820002885] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F, Jalalian FA. Complexity on modulation of NF-κB pathways by hepatitis B and C: A double-edged sword in hepatocarcinogenesis. J Cell Physiol 2019. [PMID: 30741410 DOI: 10.1002/jcp.28249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
21 Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol 2019; 25(1): 42-58 [PMID: 30643357 DOI: 10.3748/wjg.v25.i1.42] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
22 Nlankpe AM, Kwadzokpui PK, Adedia D, Nignan JN, Owiafe PK. Seroepidemiology of Hepatitis B and C Virus Infections: A Five-Year Retrospective Study among Blood Donors in Saboba District in the Northern Region of Ghana. Biomed Res Int 2021;2021:5599705. [PMID: 34055986 DOI: 10.1155/2021/5599705] [Reference Citation Analysis]
23 Del-Rios NHA, de Araujo LA, Martins RMB, Guimarães RA, de Matos MAD, Caetano KAA, Pinheiro RS, da Silva França DD, da Silva LN, Teles SA, Dos Santos Carneiro MA. Molecular and epidemiological aspects of hepatitis C virus infection among crack cocaine users. J Med Virol 2020;92:1239-45. [PMID: 31746475 DOI: 10.1002/jmv.25632] [Reference Citation Analysis]
24 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Gómez-Torres ME, Ribas-Aparicio RM, de la Luz Martínez-Rodríguez M. Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing. J Med Virol 2018;90:1277-82. [PMID: 29508903 DOI: 10.1002/jmv.25070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
26 Lavie M, Hanoulle X, Dubuisson J. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Front Immunol 2018;9:910. [PMID: 29755477 DOI: 10.3389/fimmu.2018.00910] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
27 Stournaras E, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol 2018;30:1277-82. [PMID: 30179906 DOI: 10.1097/MEG.0000000000001254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Ye D, Tang Y, Gu Y, Haleem H, Zhang L, Zhang Y, Xu C, Zhao J. Evaluation of the effectiveness of a pilot study of hospital-based hepatitis C epidemic surveillance. Medicine (Baltimore) 2019;98:e18334. [PMID: 31860986 DOI: 10.1097/MD.0000000000018334] [Reference Citation Analysis]
29 Coutinho C, Bastos LS, da Mota JC, Toledo L, Costa K, Bertoni N, Bastos FI. The risks of HCV infection among Brazilian crack cocaine users: incorporating diagnostic test uncertainty. Sci Rep 2019;9:443. [PMID: 30679480 DOI: 10.1038/s41598-018-35657-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Walker MR, Leung P, Eltahla AA, Underwood A, Abayasingam A, Brasher NA, Li H, Wu BR, Maher L, Luciani F, Lloyd AR, Bull RA. Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Sci Rep 2019;9:13300. [PMID: 31527718 DOI: 10.1038/s41598-019-49454-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
31 Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018; 6(13): 589-599 [PMID: 30430114 DOI: 10.12998/wjcc.v6.i13.589] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 71] [Article Influence: 23.8] [Reference Citation Analysis]
32 Santana MS, Lopes R, Peron IH, Cruz CR, Gaspar AM, Costa PI. Natural Bioactive Compounds as Adjuvant Therapy for Hepatitis C Infection. CNF 2021;17:458-69. [DOI: 10.2174/1573401316999201009152726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
34 Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M. Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. J Virol 2018;92:e00939-18. [PMID: 30068644 DOI: 10.1128/JVI.00939-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
36 Moustafa RI, Dubuisson J, Lavie M. Function of the HCV E1 envelope glycoprotein in viral entry and assembly. Future Virology 2019;14:171-84. [DOI: 10.2217/fvl-2018-0180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]